In the INFORM trial, neoadjuvant single-agent cisplatin did not yield superior pCR rates when compared to the combination of doxorubicin and cyclophosphamide in patients with HER2 negative early BC who carry BRCA1/2 mutations (96). The gene discussed is ERBB2; the disease is breast cancer.